Treatment of age-related macular degeneration using retinal stem and progenitor cells
The aim of the project is to develop a biomedical cell product based on retinal pigment epithelium cells for highly effective treatment age-related macular degeneration; to conduct the clinical trials of the biomedical cell product in the treatment of age-related macular degeneration.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Cultured retinal stem and progenitor cells injected subretinally
Standard treatment of age-related macular degeneration according to the clinical protocols
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Minsk, Belarus
Visual acuity
Determination of visual acuity after the therapy
Time frame: 1 month
Visual acuity
Determination of visual acuity after the therapy
Time frame: 1 year
Adverse effects associated with the therapy
Determination of adverse effects associated with the therapy
Time frame: 1 month
Adverse effects associated with the therapy
Determination of adverse effects associated with the therapy
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.